Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Impressive pathological complete response rates with immunotherapy in triple-negative breast cancer

Impressive pathological complete response rates with immunotherapy in triple-negative breast cancer

In stage 2 and 3, triple-negative breast cancer patients who had received no prior treatment, two presurgical (neoadjuvant) treatments were compared: immunotherapy plus chemotherapy and the standard treatment, chemotherapy alone. In this context, the immunotherapy atezolizumab + chemotherapy resulted in a statistically and clinically significant increase in the pathological complete response rate compared with placebo + chemotherapy.

  • This benefit was seen regardless of programmed death-ligand 1 (PD-L1) status.
  • No new safety concerns/side effects emerged.
  • The new combination may offer a better treatment option for this patient group.

What is a pathological complete response? The outcome showing how effective preoperative shrinkage is comes from the surgical pathology result. If no cancer cells are found in the surgical pathology after neoadjuvant treatment, this is called a pathological complete response. Patients with a pathological complete response have a lower likelihood of cancer recurrence.

Why this study is important

  • Triple-negative breast cancer is typically associated with high recurrence (relapse) and metastasis rates.
  • As a breast cancer subtype with no hormonal or targeted treatment options, it requires the development of new treatments.

IMpassion031 study design

  • IMpassion031 is a randomized, multicenter, placebo -controlled, double-blind phase 3 clinical trial.
  • The study enrolled 333 previously untreated patients with stage 2 and 3 triple-negative breast cancer and tumor size > 2 cm.
  • Patients were randomly assigned to two arms: 165 to atezolizumab plus chemotherapy and 168 to placebo plus chemotherapy.
  • Atezolizumab was given at 840 mg every 2 weeks; chemotherapy consisted of 12 weeks of nab-paclitaxel followed by 8 weeks of doxorubicin/cyclophosphomide.
  • The primary endpoints measured in the study were pathological complete response rates in the entire patient population and in PD-L1-positive patients.
  • Secondary endpoint: event-free survival.
  • Funding: F. Hoffmann-La Roche, Ltd.

Key results

  • Median follow-up: 20.6 months with atezolizumab and 19.8 months with placebo.
  • Pathological complete response rate: 57.6% with atezolizumab and 41.1% with placebo (difference, 16.5%; P = 0.0044).
  • Pathological complete response in patients with PD-L1-positive disease (152 people): 68.8% with atezolizumab and 49.3% with placebo (difference, 19.5%; one-sided P = 0.021; not significant).
impassion031 impressive pathological complete response rates with immunotherapy in triple-negative breast cancer
  • Median event-free survival was not reached in either group.
  • Rates of commonly reported side effects were relatively similar between the groups and were mainly associated with chemotherapy.
  • Serious treatment-related side effects: 22.6% with atezolizumab and 15.6% with placebo.

Comment

The IMpassion031 study provides very important information about the benefits of immunotherapy in preoperative treatment of previously untreated patients with stage 2 and 3 triple-negative breast cancer: not only in terms of efficacy, but also because only modest increases in side effects were seen, as expected when adding an immunotherapy.

Sources

Harbeck N et al. IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). Abstract LBA11. Presented 20 September at ESMO Virtual Congress 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Impressive pathological complete response rates with immunotherapy in triple-negative breast cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy